Skip to main content
. 2018 Sep 15;20(10):1083–1093. doi: 10.1016/j.neo.2018.08.010

Figure 5.

Figure 5

GPR30-specific agonist increases proliferation of cervical adenocarcinoma cells. (A-B) WST-8 assay. Cell proliferation was increased by G1 treatment in CAC-1 (A) and HCA1 (B) cells. (C-D) Bromodeoxyuridine (BrdU) incorporation (red) was increased by G1 treatment (10 nM, 24 hours) in CAC-1 (C) and HCA1 (D) cells. Bar graphs show the percentage of BrdU-positive cells. *P < .05.